- Home
- CVGW vs TSHA Comparison
CVGW vs TSHA Comparison
Compare CVGW & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVGW
- TSHA
- Stock Information
- Founded
- CVGW 1924
- TSHA 2019
- Country
- CVGW United States
- TSHA United States
- Employees
- CVGW N/A
- TSHA N/A
- Industry
- CVGW Specialty Foods
- TSHA Biotechnology: Pharmaceutical Preparations
- Sector
- CVGW Consumer Discretionary
- TSHA Health Care
- Exchange
- CVGW Nasdaq
- TSHA Nasdaq
- Market Cap
- CVGW 429.3M
- TSHA 397.8M
- IPO Year
- CVGW N/A
- TSHA 2020
- Fundamental
- Price
- CVGW $26.69
- TSHA $2.79
- Analyst Decision
- CVGW Strong Buy
- TSHA Strong Buy
- Analyst Count
- CVGW 1
- TSHA 7
- Target Price
- CVGW $35.00
- TSHA $7.57
- AVG Volume (30 Days)
- CVGW 210.1K
- TSHA 4.9M
- Earning Date
- CVGW 06-09-2025
- TSHA 05-15-2025
- Dividend Yield
- CVGW 3.00%
- TSHA N/A
- EPS Growth
- CVGW N/A
- TSHA N/A
- EPS
- CVGW 0.54
- TSHA N/A
- Revenue
- CVGW $688,323,000.00
- TSHA $7,224,000.00
- Revenue This Year
- CVGW $8.87
- TSHA N/A
- Revenue Next Year
- CVGW $5.49
- TSHA N/A
- P/E Ratio
- CVGW $34.46
- TSHA N/A
- Revenue Growth
- CVGW 16.87
- TSHA N/A
- 52 Week Low
- CVGW $20.30
- TSHA $1.05
- 52 Week High
- CVGW $30.58
- TSHA $4.32
- Technical
- Relative Strength Index (RSI)
- CVGW 52.68
- TSHA 62.19
- Support Level
- CVGW $25.32
- TSHA $2.66
- Resistance Level
- CVGW $26.96
- TSHA $2.97
- Average True Range (ATR)
- CVGW 0.74
- TSHA 0.25
- MACD
- CVGW 0.02
- TSHA -0.02
- Stochastic Oscillator
- CVGW 56.61
- TSHA 52.38
About CVGW Calavo Growers Inc.
Calavo Growers Inc is in the avocado industry and an expanding provider of value-added fresh food. The company distributes its products both domestically and internationally and reports its operations in two different business segments: Grown and Prepared. The Grown segment consists of fresh avocados, tomatoes, and papayas. The Prepared segment comprises all other products including fresh-cut fruits and vegetables, ready-to-eat sandwiches, wraps, salads and snacks, guacamole, and salsa sold at retail and food service as well as avocado pulp sold to food service.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.